(2R,3S)-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]-3-(4-氟苯基)吗啉盐酸盐的合成

对甲氧基苯甲醛(3)和2-氨基乙醇进行还原胺化反应得2-(4-甲氧基苄胺基)乙醇(4),4和乙醛酸经成环反应得2-羟基-4-对甲氧基苄基吗啉-3-酮(5),5和三氟乙酐反应得6后与(R)-1-[3,5-二(三氟甲基)苯基]乙醇(7)缩合,再经结晶诱导不对称转化、格氏反应、氢化脱保护及成盐反应制得阿瑞吡坦关键中间体(2R,3S)-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]-3-(4-氟苯基)吗啉盐酸盐,总收率约18%(以3计)。     

2-正丁基-1,3-二氮杂螺[4,4]壬-1-烯-4-酮的合成

目的：合成2－正丁基－1，3－二氮杂螺[4,4]-壬－1－烯－4－酮。方法：以环戊酮合成的1－氨基环戊酸为起始原料。结果：1－氨基环戊酸经过酯化，与戊亚氨酸乙酯缩合得目标化合物。结论：该合成工艺有一定改进。     

[1,2,4]三氮唑并[1,5-a]嘧啶类化合物的合成及其抗肿瘤活性

目的寻找具有抗肿瘤活性的新化合物,设计合成[1,2,4]三氮唑并[1,5-a]嘧啶衍生物,并评价其体外抗肿瘤活性。方法以γ-丁内酯为起始原料,经环合、氯代、取代、硫醚化和氨甲基化等反应合成7-苯基氨基-2-[3-(5-取代氨基甲基-呋喃-2-基-甲硫基)丙基]-5-甲基-[1,2,4]三氮唑并[1,5-a]嘧啶类化合物。采用MTT法,以顺铂为阳性对照药,以Bel-7402和HT-1080为测试细胞株对目标化合物的抗肿瘤活性进行了评价。结果与结论合成了12个未见文献报道的新化合物,结构经质谱、红外光谱和核磁共振氢谱确证。体外活性实验表明:化合物16显示出很好的抗肿瘤活性。     

4，6—二氯—2—甲基—5—[（1—乙酰基—四氢咪唑—2—亚基）氨基]嘧啶合成工艺改进

4,6-二氯 - 2 -甲基 - 5- [(1 -乙酰基 -四氢咪唑 - 2 -亚基 )氨基 ]嘧啶 (1 )是合成抗高血压药物莫索尼定(moxonidine)的重要中间体。文献 [1] 以 4,6-二氯 - 2 -甲基 - 5-氨基嘧啶 (2 )和 1 -乙酰基 - 2 -四氢咪唑酮 (3)在三氯氧磷中 ,于 50°C反应 48h,蒸除三氯氧磷 ,残留物倒入冰水中 ,用碳酸氢钾调至 p H8,以氯仿萃取 ,蒸除氯仿后以甲醇 -乙酸乙酯重结晶得产品 ,收率 52 %。我们按文献操作时 ,发现因后处理所用碳酸氢钾碱性太弱 ,因而用量多 ,且产生大量的气泡 ,操作繁琐。中和后析出很多固体 ,造成萃取困难 ,氯仿用量大 ,提取次数多…     

3-碘-1H-吡唑并[3,4-b]吡嗪的合成

2-氰基吡嗪和氯化亚砜在DMF作用下反应得3-氯-2-氰基吡嗪,经水合肼闭环得3-氨基-1H-吡唑并[3,4-6]吡嗪,再经NaNO_2/p-TsOH/K1一步完成重氮化-碘代反应得到3-碘-1H-吡唑并[3,4-b]吡嗪,总收率约31%.     

6-甲氧基-2-(4-甲氧苯基)苯并[b]噻吩及其异构体的合成研究

目的 合成盐酸雷洛昔芬关键中间体6-甲氧基-2-(4-甲氧苯基)苯并Lb]噻吩。方法 以4-甲氧基苯乙酮为原料，经溴代、硫醚化先制得α-(3—甲氧苯硫基)-4-甲氧基苯乙酮，再在多聚磷酸(PPA)的催化下，经环合及重排制得目标产物。结果 与结论从目标产物母液中分离得到3个异构体，它们的化学结构根据高分辨质谱、核磁共振氢谱与红外光谱测试数据确认。改用甲硝酸为催化剂，可提高目标产物的收率。     

N-[2-(4-甲氧基苯基)-1-甲基乙基]苄胺的制备

以1-（4-甲氧基苯基）丙酮-2和N-苄基甲酰胺为原料,采用“一锅法”,经N-苄基化、Leuckart反应和酸性水解制得福莫特罗的重要中间体N-[2-（4-甲氧基苯基）-1-甲基乙基]苄胺,总收率约46%。     

6-甲氧基-7-[(1-甲基-4-哌啶)甲氧基]-4(3H)-喹唑啉酮的合成工艺研究

目的 对6-甲氧基-7-[(1-甲基-4-哌啶)甲氧基]-4(3H)-喹唑啉酮的合成工艺进行研究.方法 以1-叔丁氧羰基-4-对甲苯磺酰氧甲基哌啶和香草酸甲酯为起始原料,经过脱叔丁氧羰基、甲基化、硝化、还原,最后经Niementowski环合得到.结果 实验总收率约为56％.结论 优化的新工艺减少了反应步骤、降低了制备成本、简化了反应操作条件、提高了产率,更适合工业化生产.     

5-HT1A受体拮抗剂WAY-100635的合成

2-氨基吡啶和2-氯乙酰氯经酰胺化、与N'-(邻甲氧基苯基)哌嗪缩合、氢化铝锂还原得4-(邻甲氧基苯基)-1-[2-[(2-吡啶基)氨基]乙基]哌嗪,再与环己甲酰氯缩合得到5-HT1A受体拮抗剂WAY-100635,总收率35%.     

1-[2-(2,4-二氟苯基)-2,3-环氧丙基]-1H-1,2,4-三唑甲烷磺酸盐的合成

1- [2 - ( 2 ,4-二氟苯基 ) - 2 ,3-环氧丙基 ]- 1 H- 1 ,2 ,4-三唑甲烷磺酸盐 ( 1 )是合成氟康唑等抗真菌药物的关键中间体。文献 [1]以间二氟苯 ( 2 )为原料 ,与氯乙酰氯反应生成 α-氯 - 2 ,4-二氟苯乙酮 ( 3) ,3在甲苯中与三唑反应生成 2 ,4-二氟 - α- ( 1 H- 1 ,2 ,4-三唑 - 1 -基 )苯乙酮 ( 4 ) ,4与 ylid试剂碘化三甲基硫盐反应形成环氧化物 ,再与甲磺酸成盐得到 1。此法第 2步和第 3步收率均很低 ,分别为 8.7%和2 1 .84% ,成品生产成本较高。本文参照文献 [2 ]的相转移催化三唑烷基化方法 ,以 TEBA为相转移催化剂 ,K2 CO3 为…     

4-[[1-[(4-氟苯基)甲基]-1H-2-苯并咪唑基]氨基]-1-哌啶甲酸乙酯的合成

以邻苯二胺为起始原料，经过缩合、氯代、烷基化和取代反应来合成4-[[1-[（4-氟苯基）甲基]-1H-2-苯并咪唑基]氨基]-1-哌啶甲酸乙酯。该合成方法操作简单，总收率达到30．7％。     

Synthesis of the new alpha- and beta-adrenergic antagonist 1-[1-(2-benzodioxanylmethyl)-4-piperidyl]amino-3-(1-naphthoxy)-2- propanol

The synthesis and in vitro alpha- and beta-adrenergic blocking potency of 1-[1-(2-benzodiaxanylmethyl)-4-piperidyl]amino-3-(1-naphthoxy-2-pr opanol (I) are described. Thus, N-benzyl-4piperidone was protected and debenzylated to the carbamate (V), which upon alkaline hydrolysis and acylation gave benzodioxanic amide (IX). Reduction of the amide group, deprotection of the ketone function of (X), and reductive amination gave the 4-aminopiperidine (XIII), which was finally condensed with the appropriate epoxide to yield the aminopropanol (I). Compound (I) is formally derived from a combination of piperoxan (II) and propranolol (III), and was approximately 10 times less potent than each one of these drugs, as an alpha- and beta-adrenergic blocker respectively.     

6,7-二氢-5H-环戊烯并[b]吡啶的合成

己二酸二乙酯经缩合、氨化、闭环、水解后脱羧、氯化及脱氯等6步反应制得头孢匹罗的中间体6，7-二氢-5H-环戊烯并[b]吡啶，总收率31％。     

Conformationally restricted phenothiazine neuroleptics. 1. 3-(Dimethylamino)-1,2,3,4-tetrahydroazepino[3,2,1-kl]phenothiazine

A rigid analogue of promazine, 3-(dimethylamino)-1,2,3,4-tetrahydroazepino[3,2,1-kl]phenothiazine (1), was prepared by reductive amination of the corresponding ketone 4. An X-ray crystallographic study revealed that the seven-membered ring of the hydrochloride salt of 1 exists as a half-chair-like form with the dimethylammonium group in an equatorial-like conformation. Compound 1 was approximately one-half as active as promazine as an inhibitor of [3H]spiperone binding in rat corpus striatal homogenates. In homogenates obtained from calf caudate tissue, however, 1 was only about one-twentieth as active as promazine as an inhibitor of [3H] spiperone binding. As a stimulator of homovanilic acid (HVA) synthesis in rat corpus striatum in vivo, it was about one-tenth as active as promazine.     

4-氨基-7-硝基苯并[1,2,5]噁二唑的合成

以2，6－二氯苯胺为原料，通过氧化环化、硝化、叠氮化、氨化等5步反应，得到4－氨基－7－硝基苯并[1,2,5]恶二唑，并对反应条件、精制方法进行了改进。总收率20．1％。     

Antibacterial, antifungal and anticonvulsant evaluation of novel newly synthesized 1-[2-(1H-tetrazol-5-yl)ethyl]-1H-benzo[d][1,2,3]triazoles

Several novel 1-[2-(1H-tetrazol-5-yl) ethyl]-1H-benzo[d][1,2,3]triazoles (3a-h) have been synthesized by the condensation of 1-[2-(1H-tetrazol-5-yl)-ethyl]-1H-benzotriazole (2) and appropriate acid chlorides. 1-[2-(1H-tetrazol-5-yl)-ethyl]-1H-benzotriazole (2) was synthesized by reacting 3-(1H-benzo[d][1,2,3]triazol-1-yl)propanenitrile with sodium azide and ammonium chloride in the presence of dimethylformamide. The synthesized compounds were characterized by IR and PMR analysis. The titled compounds were evaluated for their in-vitro antibacterial and antifungal activity by the cup plate method and anticonvulsant activity evaluated by the maximal electroshock induced convulsion method in mice. All synthesized compounds exhibited moderate antibacterial activity against Bacillus subtilis and moderate antifungal activity against Candida albicans. Compounds 5-(2-(1H-benzo[d][1,2,3]triazo-1-yl)ethyl)-1H-tetrazol-1-yl)(4-aminophenyl)methanone 3d and 5-(2-(1 H-benzo[d][1,2,3]triazo-1-yl)ethyl)-1H-tetrazol-1-yl)(2-aminophenyl)methanone 3e elicited excellent anticonvulsant activity.     

Synthesis of 1-[15N]amino-2-propanol hydrochloride

1-[¹⁵N]Amino-2-propanol hydrochloride ( 2 ) was synthesized in three steps, i.e. Gabriel condensation of potassium [¹⁵N]phthalimide ( 3 ) with chloroacetone ( 4 ), reduction of the product ([¹⁵N]phthalimidoacetone ( 5 )) with sodium borohydride, and hydrolysis in 33% total yield from the ¹⁵N-source. Copyright © 2007 John Wiley & Sons, Ltd.     

Synthesis of 2-(4-substitutedbenzyl-[1,4]diazepan-1-yl)-n-(1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamides as inotropic agents

In an attempt to search for more potent positive inotropic agents, a series of N-(4,5-dihydro-1-methyl-[1,2,4]triazolo[4,3-a]quinolin-7-yl)-2-(substitutedbenzyl-[1,4]diazepan-1-yl)acetamides were synthesized and evaluated for positive inotropic activity by measuring left atrium stroke volume in isolated rabbit heart preparations. Some of these derivatives exhibited favorable activity compared with the standard drug, milrinone, among which 2-(4-(4-methylbenzyl)-[1,4]-diazepan-1-yl)-N-(4,5-dihydro-1-methyl-[1,2,4]triazolo[4,3-a]quinolin-7-yl)acetamide (6m) was the most potent, increasing stroke volume by 8.38±0.16% (milrinone 2.45± 0.06%) at 3 x 10(-5) m. The chronotropic effects of those compounds having inotropic effects were also evaluated in this work.     

Synthesis of [4,6-3H]-2-pyridone and [3H]-RS-91309

We describe herein, a novel synthesis of the previously unreported compound, 4,6-dibromo-2-pyridone (3) and its use in the preparation of [³H]-RS-91309, a potassium channel modulator. This key intermediate, (3) , was reduced with carrier free tritium gas to furnish [4,6-³H]-2-pyridone (9) having a specific activity of 50 Ci/mmole. Condensation of (9) with epoxide (10) , followed by elaboration of the resulting chromene methyl group of (12) gave [³H]-RS-91309 (14) whose specific activity was also 50 Ci/mmole. This chemistry, as well as the solution of several microscale related stoichiometry problems is discussed.     

Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-Tumor Agents

A series of 2,5,7-trisubstituted pyrimido[4,5-d]pyrimidine cyclin-dependent kinase (CDK2) inhibitors is designed and synthesized. 6-Amino-2-thiouracil is reacted with an aldehyde and thiourea to prepare the pyrimido[4,5-d]-pyrimidines. Alkylation and amination of the latter ones give different amino derivatives. These compounds show potent and selective CDK inhibitory activities and inhibit in vitro cellular proliferation in cultured human tumor cells.